Objectives-The purpose of this study was to investigate whether thoracic ascending aortic aneurysm (TAAA) induces platelet activation as mural thrombus participates in aortic dilatation in abdominal aortic aneurysm and TAAA are associated with rheological factors favoring coagulation activation. Methods and Results-We studied the relation between coagulation activation and aortic diameter in Marfan patients (MFS) with various aortic diameters (nϭ52). We then studied patients presenting large aneurysms associated with bicuspid aortic valve (BAV) and degenerative form. Lastly, we used immunochemistry and biochemistry to investigate prothrombin/thrombin retention within the aortic wall. Microparticles, sGPV, tissue factor, and TAT complexes were increased in plasma from MFS with large aneurysms (Ն45 mm) compared to MFS with limited aortic dilatation (Ͻ45 mm). Similar elevations were observed in all patients with large aortic aneurysms, regardless of the etiology, the site of maximal aortic dilation, associated valvulopathy, risk factors, or treatments. P-selectin and platelet-bound fibrinogen were also increased, demonstrating platelet activation in large aneurysms. Significant increase in sCD146 plasma concentration suggested alteration of endothelium. Conclusions-Platelet activation occurs in patients with large aneurysms of the ascending aorta, is dependent on aortic dilation, and is associated with thrombin generation, part of which appears to be retained in mucoid degeneration areas.
T horacic ascending aortic aneurysms (TAAA) are defined by an enlargement of the ascending aorta. TAAA can be observed in old patients without clear etiologic factors, in whom it represents a primary degenerative pathology of the ascending aorta. 1 But it can also occur in the younger population; it is then usually linked to a genetic or congenital disease. Marfan syndrome represents the majority of these cases. This is usually related to mutations in fibrillin1 2 and rarely to mutations in transforming growth factor (TGF)␤R 2, which can also be responsible for Loeys-Dietz Syndrome and familial aortic aneurysm. [3] [4] [5] Other molecular abnormalities have been implicated, such as mutations in myosin, 6 TGF␤R 1 , 5 ACTA2, 7 or other currently unknown genes. 8 Moreover, bicuspid aortic valves (BAV), which may be familial, 9 are associated with a high risk of aneurysm of the ascending aorta. 10 In contrast to their etiologic diversity, all localized aortic dilations share common rheological characteristics. In normal human aorta, the regular geometry (tubular shape and parallel walls) results in laminar blood flow and in a homogeneous shear rate, maintaining a physiological steady-state among the blood components and between the circulating blood and arterial wall. 11 Changes in arterial geometry considerably modify rheological parameters and therefore influence interactions between blood components. 11, 12 The modulations by shear stress of platelet interactions with von Willebrand factor (vWF) exemplify the role of rheology in hemostasis. 13, 14 In this respect, an aneurysm of the ascending aorta induces rheological perturbations, characterized by vortices (low wall shear rate). 15 Rheological disturbances have been suggested to play a role in mural thrombus formation associated with cerebral artery and abdominal aortic aneurysms, and the luminal thrombus appears to play a role in the progression of aortic dilation. 16 In contrast with this localization, TAAAs are characterized by the absence of any mural thrombus formation 1 (Figure 1 ) even in older patients with diffuse atherosclerosis. Therefore, TAAA offers a unique opportunity to test the hypothesis that platelets and the coagulation cascade could be activated by dilation of the ascending aorta, and could be associated with this pathology independently of a mural thrombus formation. There have been no clinical studies focusing on the hemostasis cascade in patients with TAAA. For this purpose, we explored markers of activation of both platelets and prothrombin in patients with TAAA. In a first step, we compared Marfan patients with various aortic diameters and matched controls. In a second step, we studied platelets and prothrombin activation in patients presenting TAAA of other aetiologies (BAV and degenerative).
Materials and Methods

Population
One hundred fifty-six patients were divided into 4 groups (Table 1) : Healthy individuals (Controls, nϭ66); Patients fulfilling international criteria for Marfan syndrome (MFS). 17, 18 They were subdivided into 2 groups: MFS patients with limited dilation (maximal aortic diameter Ͻ45 mm) (nϭ28), and MFS patients with large aneurysm 19 (aortic diameter Ն45 mm) (nϭ24); TAAA patients scheduled for surgery because of aortic dilatation. Here, large aneurysms were associated with bicuspid aortic valves (BAV) (nϭ15), or were isolated with no sign of genetic disease (Degenerative; nϭ23). For more details, please see the supplemental data section, available online at http://atvb.ahajournals.org.
Results
Patient Groups
Clinical and echocardiographic data are summarized in Table  1 . MFS patients were significantly younger (PϽ0.01) than those of the BAV and degenerative groups. Patients from the degenerative group were the oldest with, as expected, more cardiovascular risk factors ( 2 ϭ10.5, PϽ0.01), mainly hypertension, a higher frequency of medications, and a higher incidence of significant aortic valve regurgitation (PϽ0.01).
Aortic valve stenosis was present more frequently in the BAV group ( 2 ϭ7.8, PϽ0.01). In this group, maximal aortic dilation was observed above the sinotubular junction ( 2 ϭ20, PϽ0.0001), whereas it was maximal at the level of the Valsalva sinuses in MFS patients, and the patients with degenerative aortic aneurysm.
Marfan and Controls: Relation of Platelet Activation to Aortic Diameter
No increase in plasma markers of platelet activation was observed in the group of MFS with limited dilatation (ie, maximal diameter Ͻ45 mm), when compared to age-and sex-matched control: microparticle count (Annexin-V positive) and concentrations of sGPV, Tissue factor and TAT were similar in the 2 groups (Table 2 ). In contrast, all these markers were significantly higher in plasma from MFS patients with large aneurysms (Ն45 mm) ( Table 2 ). The increase in microparticle concentration ( Figure 1 ) was correlated to aortic diameter (PϽ0.05, r 2 ϭ0.38) in the Marfan group with and without large aneurysms. Similar results were found for sGPV concentration (PϽ0.001, r 2 ϭ0.56), and these 2 markers of platelet activation were highly correlated in the whole Marfan group (PϽ0.0001, r 2 ϭ0.65).
Extension to Other Aetiologies of TAAA
Microparticles
Microparticle counts were increased in plasma of patients with large aneurysms of all etiologies (Marfan, BAVassociated or degenerative) when compared to controls (PϽ0.0001) ( Table 2 ). However, plasma levels of microparticles were similar, regardless of etiology ( Table 2 ) of large aneurysms. 93.2Ϯ3.9% of microparticles were positive for CD41 antibody (integrin GPIIb/IIIa) in patients with large aneurysms and 90.9Ϯ6.4 in controls (NS) demonstrating their platelet origin in both cases.
Plasma Markers
Other markers for platelet activation (sGPV, sCD40L) were also significantly (PϽ0.0001) higher in plasma of patients with large aneurysms than in that from controls, with no difference between etiologies ( Table 2 ). In contrast, the plasma concentration of sP-selectin was not increased in association with large aneurysms compared to controls (36.2Ϯ1.7 ng/mL versus 34.2Ϯ1.8, ns). We observed no difference in these plasma markers when patients were under low doses of aspirin. Aspirin blocks thromboxane A2 synthesis and platelet recruitment by this secreted TxA2. It thus limits the secondary progression of platelet activation, but does not block primary platelet activation. 20
Platelet Markers
Platelet membrane expression of P-selectin, measured with FACs on whole blood, was low, but significantly higher in large aneurysms compared to controls (4.08Ϯ0.53% positive versus 2.91Ϯ0.56% in controls, PϽ0.05). Similar but more significant results were obtained by analyzing the curve shift induced by the specific antibody as compared to a nonrelevant antibody (Overton method) (large aneurysms versus controls: 14.6Ϯ2.1% versus 7.8Ϯ0.6%, PϽ0.01) ( Figure 1A and 1B). P-selectin expression on platelets did not differ with regard to etiology.
Conversely, platelet-bound fibrinogen was not significantly different in large aneurysm patients compared to controls when measured by the classical analysis method (0.96Ϯ0.29% versus 0.89Ϯ0.21%, ns). However, curve shift analysis (Overton) revealed a small significant shift of the signal to the right in platelets originating from patients with large aneurysms (TAAA: 7.34Ϯ1.3% versus controls: 3.9Ϯ0.5%, PϽ0.05, Figure 1B ).
Markers of Prothrombin Activation
In plasma of patients with large aneurysms, TF antigen concentration was significantly higher than in control plasma, regardless of etiology ( Table 2 ). The 1-step recalcification clotting time was reduced for plasma of patients with large aneurysms compared to controls (175.8Ϯ8.0 seconds versus 210.7Ϯ7.9 seconds, PϽ0.001; Figure 2 ). The involvement of TF activity in the shortening of the clotting time was demonstrated by adding a blocking anti-TF antibody that prolonged the clotting time of patients with large aneurysms by 35.9Ϯ5.8%, to reach a value similar to that of controls. Plasma thrombin generation, measured using a global assay, showed an increased "endogenous thrombin potential" (ETP) for large aneurysms relative to controls (1902.3Ϯ74 nM.min Ϫ1 for TAAA versus 1712.8Ϯ63.7 nM.min Ϫ1 for controls, PϽ0.05; Figure 2 ) and an increased maximal thrombin generation (peak height) for the large aneurysm group (335.3Ϯ13.2 nmol/L versus 284.5Ϯ10.6 nmol/L for controls, PϽ0.001; Figure 2 ). Interestingly, there was a significant correlation between sGPV and maximal thrombin generation (r 2 ϭ0.49, PϽ0.01) in plasma of patients with large aneurysms. Furthermore, TAT complexes were also slightly but significantly increased in the plasma of patients with large aneurysms (PϽ0.001, Table 2 ). These results were statistically similar for all aetiologies. 
Endothelial Plasma Markers
Soluble vascular cell adhesion molecule (VCAM)-1 was not statistically different in large aneurysm and control groups (377.6Ϯ48.4 ng/mL versus 293.3Ϯ36.1 ng/mL, Pϭ0.08). In contrast, sCD146 plasma levels were significantly higher in patients with large aneurysm than in controls, with no significant differences whatever the etiology of the TAAA ( Table 2 ).
Inflammatory Markers
Fibrinogen and hsCRP levels were similar in large aneurysm patients and controls (2.8Ϯ0.1 g/L versus 2.6Ϯ0.2 g/L and 1.88Ϯ0.3 mg/L versus 1.47Ϯ0.2 mg/L, respectively). These markers were slightly, but not significantly, superior in degenerative group. This is consistent with greater age and the presence of more risk factors in this group.
Aortic Tissue Samples and Conditioned Media
In control aortic tissue, immunoreactivity for prothrombin/ thrombin (II/IIa) was negative ( Figure 3A) . In contrast, aortic sections from patients with surgically removed large aneurysms, whatever the etiology, showed prominent immunoreactivity for factor II and IIa in the mucoid areas, which were localized in serial sections stained with Alcian blue ( Figure 3A) . These results were confirmed on conditioned media of aortic samples, where factor II and IIa were detected by immunoblotting ( Figure  3B ). Conditioned media from large aneurysms expressed larger bands of prothrombin and thrombin than conditioned media from controls. By ELISA, a higher concentration of TAT was detected in conditioned media of large aneurysms, regardless the etiology as compared to controls, supporting the immunohistological and immunoblot data ( Figure 3C ).
Discussion
Our main result is the presence of biological signs of in vivo activation of both platelets and prothrombin in patients with thoracic ascending aortic aneurysm. This activation is only present when maximal aortic diameter is greater than 45 mm in Marfan patients of young age, devoid or risk factors, but not observed in MFS patients when maximal aortic diameter is less than 45 mm. It is also present in patients presenting large aneurysms of other aetiologies (BAV, Degenerative), and is not dependant on the location of the aneurysm (maximal dilation of the aortic root at the level of sinuses of Valsalva or maximal dilation of the ascending aorta above the sinotubular junction). In contrast to abdominal aortic aneurysm (AAA), aneurysms of the ascending aorta are not associated with a mural thrombus, which could readily explain the presence of circulating markers of platelet and prothrombin activation. 1 Also in contrast with AAA, inflammation, which predominates in the adventitia of AAA, 21 is absent in the aortic wall obtained from TAAA, including the adventitia. 1, 22 Our peripheral measurements of plasma CRP and fibrinogen are in keeping with this observation.
It is possible that activated platelets and coagulation factors are more rapidly diluted and washed away by the particular flow conditions in the ascending aorta. Indeed, it appears that the triggering event is sufficient to initiate thrombin genera- tion and platelet activation but insufficient to permit fibrinogen clotting and platelet aggregation. Because elevation of P-selectin, a highly procoagulant mediator, 23 is only minimal, it could also limit the onset of coagulation.
The absence of any thrombus or sign of significant inflammation in TAAA raises the question of the origin of the prothrombotic markers. Our most clear-cut observation was related to the activation of platelets and prothrombin. The main trigger of the thrombin generation cascade is tissue factor (TF), 24, 25 which is constitutively expressed in tissues. 26 Plasma TF concentrations were found to be increased in patients with large aneurysms compared to controls. This signifies that higher amounts of active TF are circulating in blood from patients with large aneurysms than in blood from controls, but that TF activity is not sufficient to generate a clot, as there was no evidence of macroscopic or microscopic thrombus in TAAA patients. The increased level of TAT is in favor of in vivo thrombin generation, which is further supported by the elevated level of sGPV, a marker of platelet activation by thrombin. 27 The rate of prothrombin activation is dependent on the assembly of tenase and prothrombinase complexes, which in turn depends on the presence of surfaces enriched in negatively-charged phospholipids. 28 The increased number of microparticles of platelet origin observed in association with large aneurysms is likely to provide the phosphatidylserine-enriched membranes required to favor thrombin generation. 29 Microparticles are the main link between platelet activation and thrombin generation. 29, 30 Elevated levels of sGPV and platelet-derived microparticles in vivo indicate platelet activation by thrombin 27 in TAAA. Elevated soluble CD40L (CD154), a transmembrane protein released by proteolytic cleavage in response to various stimuli, 31 in the plasma of TAAA patients also suggests platelet activation. sCD40L release is directly related to platelet activation, 32,33 depends on metalloproteinase activities 34 and triggers TF expression on binding to CD40 on monocytes. 35 Nevertheless, because CD40L can also be released by leukocytes and endothelial cells, a nonplatelet origin of this marker cannot be completely excluded in our patients. The slight but significant increase in P-selectin expression on circulating platelets provides additional evidence for a platelet activation state in TAAA. However, when compared to the situation in AAA patients, 16 a lower level of proteolytic shedding probably occurs in TAAA patients, because plasma levels of soluble P-selectin were not significantly different from control levels. In older patients (degenerative group) or BAV patients with associated valve disease, the activation detected may not be solely related to the ascending aortic aneurysm. Indeed, in the absence of cases of ascending aortic aneurysm of diameter below 45 mm in these groups, we cannot definitively rule out the presence of platelet activation even when aortic dilatation is limited. However, this activation was not observed in the control group, nor was it related to the presence of risk factors in multivariate analysis. In contrast, Marfan patients are young and without cardiovascular risk factors or valve disease. Our MFS patients were divided according to the maximal aortic diameter (Ն45 mm) in 2 subgroups of similar age, sex, and both without risk factors or valvulopathy. The only difference between these 2 subgroups was the value of the dilation of the Valsalva sinuses, suggesting that activation of platelets and prothrombin was directly dependent on the magnitude of TAAA dilation.
The ascending aortic aneurysm location is interesting, because the normal dilation of Valsalva sinuses induces a particular, but physiological, disturbed flow. A significant dilation in this area should strongly increase these perturbations. Vortices have also been observed in vivo by magnetic resonance imaging in aneurysms of the human ascending aorta. 15, 36 An abrupt increase in lumen dimension leads to localized vortex phenomena characterized by a stagnation point and a recirculation zone in vitro. 11, 37 Jou et al reported the correlation between changes in luminal geometry and hemodynamics in fusiform intracranial aneurysms. 38 The importance of rheological factors in platelet biology and hemostatic status is now well established. 11, 39 It was also demonstrated earlier that dilation-induced vortical flow could lead to platelet activation, 14, 37 via the interaction of GPIIbIIIa and fibrinogen. 11, 40 This phenomenon could participate in the poststenotic accumulation of platelets. 41 In addition to platelets, vortices also influence red blood cell morphology and aggregate formation. 11, 42 In particular, red blood cells enhance platelet reactivity 43 and release ADP at low shear rates, 44 which could participate in platelet activation. 45, 46 Therefore, this relationship between arterial wall dilation, rheological disturbance, and platelet activation could account for the observed increase in plasma markers of platelet and prothrombin activation in patients with TAAA, regardless of their localization. 16, 47 Thrombin is able to increase endothelial cell monolayer dysfunction and permeability. 48 The elevation of soluble CD146, a protein involved in endothelial cell-cell interactions 49 in patients with TAA, suggests endothelial alteration. 50 This is compatible with an elevation of endothelial permeability to which in vivo thrombin generation could contribute. The increase in endothelial permeability could allow convection of plasma prothombin/thrombin into the aortic wall from the blood compartment. 51 Actually, we evidenced the presence of thrombin inside the pathological aortic wall using different approaches. Indeed, TAAAs are characterized histopathologically by mucoid degeneration associated with vacuole formation within the aortic media, whatever their etiology. 1, 52 The initial pathological process probably associates smooth muscle cell disappearance, mucoid degeneration, and extracellular matrix breakdown not linked to atherosclerosis. The release of TAT into the condi-tioned media indicated that active thrombin was present within the aortic media ( Figure 3 ) and could play a role in thoracic ascending aortic aneurysm pathology.
In conclusion, large aneurysms of the ascending aorta are associated with a significant level of platelet activation and thrombin generation which can be detected via a peripheral approach. This activation process is related to the magnitude of the aortic dilation, but independent of the etiology of the aneurysm. The generation of thrombin could have a direct effect on endothelial cells and on smooth muscle cells, because we found thrombin within the ascending aortic medial layer. Exploring the role of this protease in aneurysmal progression requires further studies, and may open up the perspective of new therapeutic targets in patients with aneurysm of the ascending aorta.
